The Current Challenge of Immune Globulin Access
Understanding the factors contributing to the current shortage of immune globulin could help to address a crisis that threatens dire consequences for patients.
Against the Storm: High-Dose IVIG as an Immunoregulatory Treatment Strategy for Severe COVID-19
While there may be no “magic bullet” to treat cytokine storm, one widely used immunomodulatory agent in particular — polyclonal intravenous immune globulin (IVIG) purified from healthy donor plasma — is distinguished by the simple fact that it is anything but a narrowly targeted treatment.
In Case of a Shortage: Strategies to Conserve the Immune Globulin Supply
What can be done in the event of a severe shortage of IG products, whose production is entirely reliant on a continuous supply of IgG-rich plasma donated at more than 800 dedicated U.S. collection facilities?
The Promise of COVID-19 Hyperimmune Immune Globulin Therapy
As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.
No Place Like Home: The Growing Acceptance of Subcutaneous Immune Globulin
Is SCIG well-accepted by most patients either previously treated with IVIG or just starting out on IG therapy?
FDA Approves Sandoz’s Ziextenzo as 24th Biosimilar
The U.S. Food and Drug Administration (FDA) has approved Ziextenzo (pegfilgrastim-bmez), the 24th biosimilar approval in the U.S.
A Guide to Immune Globulin Billing and Reimbursement
Reimbursement for expensive immune globulin (IG) therapies can be challenging and frustrating for providers. Here’s a guide to help ensure they are reimbursed for the cost of these medications.
Octapharma Introduces New SCIG Product and IgCares Program
Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) at the Immune Deficiency Foundation (IDF) National Conference in June.
Anti-Influenza Hyperimmune Immune Globulin Not Effective in Hospitalized Adults with Influenza Infection
A trial was conducted to assess the safety and efficacy of hIVIG (in conjunction with standard care) in adults hospitalized with laboratory-confirmed influenza A or B infection.
